Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling

I M Avis1, M Jett, T Boyle

  • 1National Cancer Institute, Biomarkers and Prevention Research Branch, Rockville, Maryland 20850-3300, USA.

Insights

Autocrine growth factors activate 5-lipoxygenase in lung cancer, increasing cell growth via 5-HETE production. Inhibiting this pathway significantly reduces tumor growth and enhances cell death, offering a new therapeutic strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Autocrine growth factors play a role in lung cancer progression.
  • Understanding shared signal transduction pathways is crucial for effective lung cancer control.

Purpose of the Study:

  • To investigate the role of 5-lipoxygenase (5-LO) in autocrine growth factor-mediated lung cancer cell growth.
  • To evaluate the therapeutic potential of inhibiting 5-LO in lung cancer.

Main Methods:

  • Assessed 5-LO activity and 5-HETE production in lung cancer cell lines stimulated by growth factors.
  • Utilized selective 5-LO antagonists to inhibit pathway activity in vitro and in vivo.
  • Examined programmed cell death levels following 5-LO pathway interruption.

Main Results:

  • Two autocrine growth factors activated 5-LO, increasing 5-HETE production and stimulating lung cancer cell growth.
  • 5-LO inhibition significantly reduced lung cancer cell line growth.
  • Interruption of 5-LO signaling in vivo led to increased programmed cell death.

Conclusions:

  • 5-Lipoxygenase activation is integral to growth factor-driven lung cancer cell proliferation.
  • Targeting the 5-lipoxygenase pathway with inhibitors presents a promising clinical strategy for lung cancer treatment.